Literature DB >> 27350164

GC-TOF/MS-based metabolomics approach to study the cellular immunotoxicity of deoxynivalenol on murine macrophage ANA-1 cells.

Jian Ji1, Jiadi Sun2, Fuwei Pi2, Shuang Zhang3, Chao Sun2, Xiumei Wang2, Yinzhi Zhang3, Xiulan Sun4.   

Abstract

Gas chromatography-time of fly/mass spectrum (GC-TOF/MS) based complete murine macrophage ANA-1 cell metabolome strategy, including the endo-metabolome and the exo-metabolome, ANA-1 cell viability assays and apoptosis induced by diverse concentrations of DON were evaluated for selection of an optimized dose for in-depth metabolomic research. Using the optimized chromatography and mass spectrometry parameters, the metabolites detected by GC-TOF/MS were identified and processed with multivariate statistical analysis, including principal componentanalysis (PCA) and orthogonal projection to latent structures-discriminant analysis (OPLS-DA) analysis. The data sets were screened with a t-test (P) value < 0.05, VIP value > 1, similarity value > 500, leaving 16 exo-metabolite variables and 11 endo-metabolite variables for further pathway analysis. Implementing the integration of key metabolic pathways, the metabolism pathways were categorized into two dominating types, metabolism of amino acid and glycometabolism. Glycine, serine and threonine metabolism, phenylalanine, tyrosine and tryptophan biosynthesis and phenylalanine metabolism were the significant amino acids affected by the metabolic pathways, indicating statistically significant fold changes including pyruvate, serine, glycine, lactate and threonine. Glycolysis or gluconeogenesis, starch and sucrose metabolism, and galactose metabolism, belonging to glycometabolism, were the pathways that were found to be primarily affected, resulting in abnormal metabolites such as glucose-1P, Glucose, gluconic acid, myo-inositol, sorbitol and glycerol.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cellular immunotoxicity; Deoxynivalenol; GC-TOF/MS; Metabolomic

Mesh:

Substances:

Year:  2016        PMID: 27350164     DOI: 10.1016/j.cbi.2016.06.017

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  6 in total

1.  Degradation of Ochratoxin A by a UV-Mutated Aspergillus niger Strain.

Authors:  Dong Zou; Jian Ji; Yongli Ye; Yang Yang; Jian Yu; Meng Wang; Yi Zheng; Xiulan Sun
Journal:  Toxins (Basel)       Date:  2022-05-16       Impact factor: 5.075

2.  The Antagonistic Effect of Mycotoxins Deoxynivalenol and Zearalenone on Metabolic Profiling in Serum and Liver of Mice.

Authors:  Jian Ji; Pei Zhu; Fangchao Cui; Fuwei Pi; Yinzhi Zhang; Yun Li; Jiasheng Wang; Xiulan Sun
Journal:  Toxins (Basel)       Date:  2017-01-10       Impact factor: 4.546

3.  Explaining combinatorial effects of mycotoxins Deoxynivalenol and Zearalenone in mice with urinary metabolomic profiling.

Authors:  Jian Ji; Pei Zhu; Ivana Blaženović; Fangchao Cui; Morteza Gholami; Jiadi Sun; Jean Habimana; Yinzhi Zhang; Xiulan Sun
Journal:  Sci Rep       Date:  2018-02-28       Impact factor: 4.379

4.  Long noncoding RNA LINC01234 promotes serine hydroxymethyltransferase 2 expression and proliferation by competitively binding miR-642a-5p in colon cancer.

Authors:  Changwei Lin; Yi Zhang; Yifei Chen; Yang Bai; Yi Zhang
Journal:  Cell Death Dis       Date:  2019-02-12       Impact factor: 8.469

5.  Kunxian Capsule for Rheumatoid Arthritis: Inhibition of Inflammatory Network and Reducing Adverse Reactions Through Drug Matching.

Authors:  Yujun Tang; Yi Zhang; Lin Li; Zhijun Xie; Chengping Wen; Lin Huang
Journal:  Front Pharmacol       Date:  2020-04-17       Impact factor: 5.810

6.  Corilagin Ameliorates Atherosclerosis in Peripheral Artery Disease via the Toll-Like Receptor-4 Signaling Pathway in vitro and in vivo.

Authors:  Yiqing Li; Yujie Wang; Yunfei Chen; Yao Wang; Shaojun Zhang; Pan Liu; Zhilin Chen; Peng Song; Lei Luo; Yingying Luo; Yiping Dang; Lei Zhao
Journal:  Front Immunol       Date:  2020-08-06       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.